Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab vs Zoledronic Acid for Bone Metastases in Prostate Cancer
NCT00321620Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2006
- Primary completion
- Oct 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial of denosumab in bone metastases, sponsored by Amgen. Primary endpoint: Time to the First On-Study Skeletal Related Event (Non-inferiority) at 40.5 months. Started Apr 2006; status: completed.
02
Drugs
denosumab
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT00321620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00321620.